Botanix Pharmaceuticals Ltd
Research Botanix Pharmaceuticals Ltd (BOT) on Bullrun: market cap AUD 46.95M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBOT
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 46.95M
- Financial periodFY2025
- RevenueAUD 5.76M
- Revenue growth856.6%
- Net income-AUD 86.40M
- Free cash flow-AUD 79.63M
- Gross margin40.3%
Valuation Snapshot
latest market cap is AUD 46.95M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 5.76M | -AUD 86.40M | -AUD 79.63M | 40.3% | -0.05 | AUD 64.97M | AUD 32.11M | AUD 81.30M |
| FY2024 | AUD 601.82K | -AUD 13.87M | -AUD 26.13M | 100.0% | -0.01 | AUD 79.31M | n/a | AUD 108.73M |
| FY2023 | AUD 102.93K | -AUD 9.15M | -AUD 19.13M | 100.0% | -0.01 | AUD 10.25M | n/a | AUD 22.95M |
| FY2022 | n/a | -AUD 13.17M | -AUD 14.11M | n/a | -0.01 | AUD 7.29M | AUD 122.41K | AUD 8.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-07 | AUD 46.95M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Botanix Pharmaceuticals Ltd's market cap?
Botanix Pharmaceuticals Ltd's market capitalization is AUD 46.95M.
What does Botanix Pharmaceuticals Ltd do?
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older.